RGEN News and Press, Repligen Corporation From 06/06/19

Investing in companies with superior growth can lead to outstanding returns over the long term. However, picking the best growth stocks is easier said than done, and a good idea without solid implementation can do more harm than good. This is especially true among growth stocks, since these ...

WALTHAM, Mass., June 04, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that Jon K. Snodgres, Chief Financial Officer, will present at the Jefferies 2019 Global Healthcare Conference on Thu...

SPDR Biotech ETF (NYSE: XBI ) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskie...

The following slide deck was published by Repligen Corporation in conjunction with this Read more ...

Repligen Corporation (RGEN) Q1 2019 Earnings Conference Call May 09, 2019, 08:30 AM ET Company Participants Sondra Newman - IR Tony Hunt - President & CEO Jon Snodgres - CFO Conference Call Participants Brandon Couillard - Jefferies Andrew Jones - Stephens Inc. Paul...

Repligen (NASDAQ: RGEN ): Q1 Non-GAAP EPS of $0.28; GAAP EPS of $0.17 beats by $0.03 . More news on: Repligen Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...

Reports first quarter revenue of $60.6 million, representing 35% year-over-year growth and 37% organic growth Raises revenue guidance to $235-$241 million for full year 2019, representing 22%-25% organic growth   Enters agreement to acquire analytics leader C Technologies Clo...

Repligen (NASDAQ: RGEN ) is scheduled to announce Q1 earnings results on Thursday, May 9th, before market open. More news on: Repligen Corporation, Earnings news and commentary, , Healthcare stocks news, Read more ...

WALTHAM, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2019 financial results on Thursday, May 9, 2019. The Company will issue a press release before the market opens and will host a conference call ...

Heron Therapeutics (NASDAQ: HRTX )  -24%  after FDA rejects application for pain med HTX-011. More news on: Heron Therapeutics, Inc., Nabriva Therapeutics plc, CM Seven Star Acquisition Corporation, Stocks on the move, Read more ...